Zevra Therapeutics Inc’s filing revealed that its Director Watton Corey Michael acquired Company’s shares for reported $2352.0 on Mar 28 ’25. In the deal valued at $7.84 per share,300 shares were bought. As a result of this transaction, Watton Corey Michael now holds 1,800 shares worth roughly $16434.0.
Then, Bode John B bought 10,000 shares, generating $79,624 in total proceeds. Upon buying the shares at $7.96, the Director now owns 40,000 shares.
Before that, Sangiovanni Timothy J. sold 3,000 shares. Zevra Therapeutics Inc shares valued at $23,588 were divested by the SVP, Finance & Corp Controller at a price of $7.86 per share. As a result of the transaction, Sangiovanni Timothy J. now holds 16,341 shares, worth roughly $0.15 million.
A number of analysts have revised their coverage, including Guggenheim’s analysts, who began to cover the stock in early October with a ‘”a Buy”‘ rating. Maxim Group also remained covering ZVRA and reiterated its “Buy” recommendation on September 24, 2024. JMP Securities started covering the stock on September 24, 2024. It rated ZVRA as “a Mkt outperform”.
Price Performance Review of ZVRA
On Friday, Zevra Therapeutics Inc [NASDAQ:ZVRA] saw its stock fall -2.56% to $9.13. Over the last five days, the stock has lost -1.40%. Zevra Therapeutics Inc shares have risen nearly 9.47% since the year began. Nevertheless, the stocks have risen 96.77% over the past one year. While a 52-week high of $9.76 was reached on 06/11/25, a 52-week low of $4.20 was recorded on 04/09/25.
Levels Of Support And Resistance For ZVRA Stock
The 24-hour chart illustrates a support level at 9.03, which if violated will result in even more drops to 8.92. On the upside, there is a resistance level at 9.28. A further resistance level may holdings at 9.43.
How much short interest is there in Zevra Therapeutics Inc?
A steep rise in short interest was recorded in Zevra Therapeutics Inc stocks on 2025-05-30, growing by 69168.0 shares to a total of 5.67 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 5.6 million shares. There was a rise of 1.22%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 02, 2024 when Maxim Group resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $18.
